首页> JAMA oncology> Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.

Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.

导出 LinkOut

翻译打印收藏纠错

第一作者： Ciara M,Kelly

第一单位： Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer Center, New York, New York.;Weill Cornell Medical College, New York, New York.;Department of Sarcoma Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

作者： Ciara M,Kelly ^[1] ; Cristina R,Antonescu ^[2] ; Timothy,Bowler ^[2] ; Rodrigo,Munhoz ^[2] ; Ping,Chi ^[3] ; Mark A,Dickson ^[4] ; Mrinal M,Gounder ^[4] ; Mary Louise,Keohan ^[4] ; Sujana,Movva ^[5] ; Reena,Dholakia ^[5] ; Hamza,Ahmad ^[5] ; Matthew,Biniakewitz ^[5] ; Mercedes,Condy ^[5] ; Haley,Phelan ^[5] ; Margaret,Callahan ^[6] ; Phillip,Wong ^[7] ; Sam,Singer ^[3] ; Charlotte,Ariyan ^[3] ; Edmund K,Bartlett ^[3] ; Aimee,Crago ^[3] ; Sam,Yoon ^[3] ; Sinchun,Hwang ^[2] ; Joseph P,Erinjeri ^[2] ; Li-Xuan,Qin ^[2] ; William D,Tap ^[4] ; Sandra P,D'Angelo ^[6]

作者单位： Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer Center, New York, New York.;Weill Cornell Medical College, New York, New York.;Department of Sarcoma Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. ^[1] Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, New York. ^[2] Weill Cornell Medical College, New York, New York.;Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, New York. ^[3] Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer Center, New York, New York.;Weill Cornell Medical College, New York, New York. ^[4] Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer Center, New York, New York. ^[5] Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer Center, New York, New York.;Weill Cornell Medical College, New York, New York.;Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York. ^[6] Evelyn H. Lauder Breast Center, Memorial Sloan Kettering Cancer Center, New York, New York.;Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York.;Immune Monitoring Facility, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York. ^[7]

主题词成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);生物制品(Biological Products);综合疗法(Combined Modality Therapy);疱疹病毒1型, 人(Herpesvirus 1, Human);人类(Humans);中年人(Middle Aged);溶瘤病毒疗法(Oncolytic Virotherapy);肉瘤(Sarcoma);治疗结果(Treatment Outcome);青年人(Young Adult)

DOI 10.1001/jamaoncol.2019.6152

PMID 31971541

发布时间 2023-06-15

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

JAMA oncology

2020年6卷3期

402-408页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.

JAMA oncology

相似文献

JAMA oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.

JAMA oncology

相似文献

JAMA oncology

相关期刊

检索历史清除